Structural & Congenital Heart Disease | March 2020

Physicians at St. Michael’s Hospital of Unity Health Toronto in Canada announced this month that they’d completed the world’s first minimally invasive tricuspid valve replacement with success.

Mount Sinai has launched an Adult Congenital Heart Disease Center at Mount Sinai Heart in New York in an attempt to streamline CHD care throughout the life cycle.

A study published in JACC: Cardiovascular Interventions this month found that patients who suffer from migraines may find long-term relief after transcatheter patent foramen ovale closure.

The largest comprehensive study of congenital heart disease to date has revealed that, despite an overall decline in mortality over the past few decades, a child’s odds of surviving a CHD diagnosis hinge on the economic health of their community.

An analysis of PARTNER 2 data published in the New England Journal of Medicine Jan. 29 suggests five-year post-op outcomes are similar among heart patients who undergo either transcatheter or surgical aortic valve replacement.

Injection drug users prescribed controlled release hydromorphone—an opioid—are three times more likely to develop endocarditis than users prescribed other opioids, according to work published Jan. 22 in The Lancet Infectious Diseases.

Palo Alto, Calif.-based nonprofit Additional Ventures announced Jan. 21 it would be awarding a total of $5.7 million to five institutions for research on single ventricle heart defects.